The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.
about
A mechanism for the synergistic antimalarial action of atovaquone and proguanilThe influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic reviewIn vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) populationThe activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyThe multiple dose pharmacokinetics of proguanil.Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian populationUsing pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation.Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development.Recent Advances in the Prophylaxis and Treatment of Malaria.The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administrationPopulation pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone.Pharmacogenetics: part II: Perspective. 1992.High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand
P2860
Q24550657-166AA932-3976-47C0-B9E7-9FB35D37EB03Q28079877-9B7E88DE-E536-4150-BE5B-B01AB7C644D0Q34346652-96824B51-D46A-4E21-9E52-E75F063E8632Q34347052-561B275D-5DBA-4EDF-BEEE-76C53073929AQ34347620-C2F0D6DA-7585-4111-A75E-CA138C0B1946Q34358893-192EB933-66A3-41D3-B0FB-9037849994D9Q34403853-A71792D3-DE2E-4E62-9D81-096CDE2C8A6FQ35802629-349B8463-98BA-4815-9430-5C04FCE70161Q36662879-DA99392F-0EF6-4FE6-B21B-340EA2E89865Q37587440-5658DFAA-132E-4E47-92E0-04067E54C172Q39155334-6470F09A-BF65-4D71-86FB-4F44C5019F8EQ39288374-DCFCAD2C-7F8B-4E51-84FF-782ED9A83691Q41931375-A67FFB03-A215-4EBB-BD59-85EB3C944FA7Q42002911-EB95E08A-2B98-4851-B6E1-D25240F0747EQ42565032-4D8DB8E9-DFC8-4E42-9402-CC0642DF669BQ48034527-C637EFB6-3594-4E48-8221-07FE87C948A5Q48543727-626B7596-BAF7-4247-94D0-8AF0E24E3A0AQ50271114-AA3357F2-EE35-4FF9-AF63-8DEE1EC3D74DQ54003849-5D286A8B-4960-410B-9066-E322CA4DB54DQ58477006-A54DD597-C1B4-46EC-B366-1E4A4296AA83
P2860
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
The pharmacokinetics and activ ...... ariability in drug metabolism.
@en
The pharmacokinetics and activ ...... ariability in drug metabolism.
@nl
type
label
The pharmacokinetics and activ ...... ariability in drug metabolism.
@en
The pharmacokinetics and activ ...... ariability in drug metabolism.
@nl
prefLabel
The pharmacokinetics and activ ...... ariability in drug metabolism.
@en
The pharmacokinetics and activ ...... ariability in drug metabolism.
@nl
P2093
P2860
P1476
The pharmacokinetics and activ ...... ariability in drug metabolism.
@en
P2093
Breckenridge AM
Howells RE
P2860
P304
P356
10.1111/J.1365-2125.1990.TB03818.X
P407
P577
1990-10-01T00:00:00Z